Please login to the form below

Not currently logged in
Email:
Password:

FDA approves drug for drooling

The US Food and Drug Administration has approved Shionogi Pharma's Cuvposa oral solution to treat chronic severe drooling in children

The US Food and Drug Administration (FDA) has approved Shionogi Pharma's Cuvposa (glycopyrrolate) oral solution to treat chronic severe drooling in children who suffer from neuromuscular dysfunction related to neurologic disorders. The drug is cleared for children aged three years to 16 years.

Glycopyrrolate, which was cleared for US marketing decades ago in tablet form as a treatment for peptic ulcers, was already frequently used off-label for the paediatric drooling indication, as it lowers the volume of saliva produced in the mouth.

The new approval is the result of a 2001 advisory committee meeting convened by the FDA "to discuss how best to develop products for drooling with ethically and scientifically sound trials in children who have neurological disorders," the agency said.

Cuvposa is a flavoured oral solution designed for ease of use in paediatric patients. When the drug was used off-label, the tablets had to be crushed and mixed with fluid, which was unpalatable to some children and also often resulted in inexact dosing.

Clinical trials of Cuvposa showed that 78 per cent of the children taking the active drug had clinical improvement in drooling, versus 19 per cent of the placebo group.

29th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics